EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Post-COVID-19 opsoclonus myoclonus syndrome

Branavan Sivagnanam, Thashi Chang

Sri Lanka Journal of Neurology · 2023

DOI: 10.4038/sljon.v10i1.146 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Sri Lanka Journal of Neurology, 2023. Verfasst von Branavan Sivagnanam und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Opsoclonus-myoclonus syndrome (OMS) is a rare neurological disorder, which most commonly is a paraneoplastic manifestation. We report a case of OMS occurring as an immunological sequalae of COVID-19.Case presentation: A 69-year-old woman developed subacute onset opsoclonus, multifocal myoclonus and truncal ataxia following moderately-severe COVID-19. Extensive evaluation revealed no underlying malignancy. There was only a partial response to steroids and intravenous immunoglobulin, but she significantly improved with plasmapheresis.

Conclusion

SARS-COV-2 infection can induce an immune-mediated OMS, which responds to plasmapheresis.

Zitieren

APA

Sivagnanam, B., & Chang, T. (2023). Post-COVID-19 opsoclonus myoclonus syndrome. Sri Lanka Journal of Neurology. https://doi.org/10.4038/sljon.v10i1.146

Vancouver

Sivagnanam B, Chang T. Post-COVID-19 opsoclonus myoclonus syndrome. Sri Lanka Journal of Neurology. 2023. doi:10.4038/sljon.v10i1.146

BibTeX
@article{Sivagnanam2023,
  author = {Sivagnanam, Branavan and Chang, Thashi},
  title = {Post-COVID-19 opsoclonus myoclonus syndrome},
  journal = {Sri Lanka Journal of Neurology},
  year = {2023},
  doi = {10.4038/sljon.v10i1.146}
}
Kostenlos starten →